Abstract
We studied the pharmacokinetics of two synthetic derivatives of 1-deoxynojirimycin in the rat after intravenous administration. The mannosidase IA/B inhibitor 1-deoxymannojirimycin and the glucosidase inhibitor N-methyl- 1-deoxynojirimycin exhibited minimal plasma protein binding and showed a rapid biphasic plasma disappearance, with an initial t 1/2 of 3.0 and 4.5 min, respectively, and a terminal t 1/2 of 51 and 32 min, respectively. For both compounds renal excretion is the major route of elimination. After 120 min, 52% of the dose of 1-deoxymannojirimycin and 80% of the dose of N-methyl- 1-deoxymannojirimycin was recovered unchanged from the urine, whereas only 4.9 and 0.2%, respectively, of the dose was excreted in bile. Urinary clearance of 1-deoxymannojirimycin was similar to the glomerular filtration rate. In contrast, urinary clearance of N-methyl- 1-deoxynojirimycin was two to three times higher than the glomerular filtration rate, indicating active tubular secretion. Ligation of the renal vessels decreased the total-body clearance of 1-deoxymannojirimycin and N-methyl- 1-deoxynojirimycin 18- and 24-fold, respectively. Neither alkalinization of the urine by infusion of bicarbonate solutions nor forced diuresis altered the renal excretion rate of these compounds, implying the absence of tubular reabsorption. At 120 min, the amounts of 1-deoxymannojirimycin in liver and kidney were 2.1 and 1.1% of the dose, respectively, while small intestine, stomach, and heart contained only 0.9, 0.6 and 0.1%. Less than 1% of the dose of N-methyl-1-deoxynojirimycin was found in the collected organs 2 hr after injection. At the same time point, the kidney/plasma concentration ratio of N-methyl- 1-deoxynojirimycin was 10-fold higher than in other tissues, whereas for 1-deoxymannojirimycin it was only 2- to 3-fold higher in kidney, indicating a more persistent general tissue retention of 1-deoxymannojirimycin.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
U. Fuhrmann, E. Bause, and H. L. Ploegh. Inhibitors of oligosaccharide processing. Biochim. Biophys. Acta 825:95–110 (1985).
A. D. Elbein. Inhibitors of the biosynthesis and processing of N-linked oligosaccharide chains. Annu. Rev. Biochem. 56:497–534 (1987).
V. Gross, T. Andus, T. A. Tran-Thi, R. T. Schwarz, K. Decker, and P. C. Heinrich. 1-Deoxynojirimycin impairs oligosaccharide processing of α1-proteinase inhibitor and inhibits its secretion in primary cultures of rat hepatocytes. J. Biol. Chem. 258:12203–12209 (1983).
V. Gross, T. A. Tran-Thi, R. T. Schwarz, A. D. Elbein, K. Decker, and P. C. Heinrich. Different effects of the glucosidase inhibitors 1-deoxynojirimycin, N-methyl-1-deoxynojirimycin and castanospermine on the glycosylation of rat α1-proteinase inhibitor and α1-acid glycoprotein. Biochem. J. 236:853–860 (1986).
J. B. Parent, T. K. Yeo, K. T. Yeo, and K. Olden. Differential effects of 1-deoxynojirimycin on the intracellular transport of secretory glycoproteins of human hepatoma cells in culture. Mol. Cell. Biochem. 72:21–33 (1986).
K. M. Robinson, B. L. Rhinehart, M. E. Begovic, C. H. R. King, and P. S. Liu. Castanospermine-glucosides are potent, selective, long-acting sucrase inhibitors. J. Pharmacol. Exp. Ther. 251:224–229 (1989).
G. Heinz, M. Komjati, A. Korn, and W. Waldhausl. Reduction of postprandial blood glucose by the α-glucosidase inhibitor Miglitol (BAY m 1099) in Type II diabetes. Eur. J. Clin. Pharmacol. 37:33–36 (1989).
M. J. Humphries, K. Matsumoto, S. L. White, and K. Olden. Inhibition of experimental metastasis by castanospermine in mice: Blockage of two distinct stages of tumor colonization by oligosaccharide processing inhibitors. Cancer Res. 46:5215–5222 (1986).
R. A. Gruters, J. J. Neefjes, M. Tersmette, R. E. Y. De Goede, A. Tulp, H. G. Huisman, F. Miedema, and H. L. Ploegh. Interference with HIV-induced syncytium formation and viral infectivity by inhibitors of trimming glucosidase. Nature 330:74–77 (1987).
L. Ratner, N. Van der Heyden, and D. Dedera. Inhibition of HIV and SIV Infectivity by blockade of alpha-glucosidase activity. Virology 181:180–192 (1991).
J. J. Neefjes, J. Lindhout, H. J. G. Broxterman, G. A. Van der Marel, J. H. Van Boom, and H. L. Ploegh. Non-carrier-mediated uptake of the mannosidase I inhibitor 1-deoxymannojirimycin by K562 erythroleukemic cells. J. Biol. Chem. 264:10271–10275 (1989).
R. Saul, R. J. Molyneux, and A. D. Elbein. Studies on the mechanism of castanospermine inhibition of α-and β-glycosidases. Arch. Biochem. Biophys. 230:668–675 (1984).
U. Fuhrmann, E. Bause, G. Legler, and H. L. Ploegh. Novel mannosidase inhibitor blocking conversion of high mannose to complex oligosaccharides. Nature 307:755–758 (1984).
M. Bollen, A. Van de Broeck, and W. Stalmans. 1-Deoxynojirimycin and related compounds inhibit glucogenolysis in the liver without affecting the concentration of phosphorylase a. Biochem. Pharmacol. 37:905–909 (1988).
M. Bollen and W. Stalmans. The antiglycogenolytic action of 1-deoxynojirimycin results from a specific inhibition of the α-1,6-glucosidase activity of the debranching enzyme. Eur. J. Biochem. 181:775–780 (1989).
G. Legler and E. Juelich. Synthesis of 5-amino-5-deoxy-D-mannopyranose and 1,5-di-deoxy-1,5-imino-D-mannitol, and inhibition of alpha-and beta-D-mannosidases. Carbohydr. Res. 128:61–72 (1984).
J. Schweden, C. Borgmann, G. Legler, and E. Bause. Characterization of calf liver glucosidase I and its inhibition by basic sugar analogues. Arch. Biochem. Biophys. 248:335–340 (1986).
R. M. Ruprecht, L. D. Bernard, R. Bronson, M. A. G. Sosa, and S. Mullaney. Castanospermine vs its 6-O-Butanoyl analog—A comparison of toxicity and antiviral activity in vitro and in vivo. J. Acquir. Immune Defic. Syndr. 4:48–55 (1991).
H. J. G. Broxterman, J. J. Neefjes, G. A. Van der Marel, H. L. Ploegh, and J. H. Van Boom. Synthesis of the antibiotic 1,5-dideoxy-1,5-imino-D-mannitol. J. Carbohydr. Chem. 7:593–603 (1988).
C. Neef, R. Oosting, and D. K. F. Meijer. Structure-pharmacokinetics relationship of quaternary ammonium compounds. Elimination and distribution characteristics. Naunyn Schmiedebergs Arch. Pharmacol. 328:103–110 (1984).
G. J. Mulder, E. Scholtens, and D. K. F. Meijer. Collection of metabolites in bile and urine from the rat. In W. B. Jakoby (ed.), Methods in Enzymology, Vol. 77 Academic Press, New York, 1981, pp. 21–30.
W. S. Bivin, M. P. Crawford, and N. R. Brewer. Morphophysiology. In H. J. Baker, J. R. Lindsey, and S. H. Weisbroth (eds.), The Laboratory Rat Academic Press, New York, 1979, pp. 73–103.
C. Neef and D. K. F. Meijer. Structure-pharmacokinetics relationship of quaternary ammonium compounds. Correlation of physicochemical and pharmacokinetic parameters. Naunyn Schmiedebergs Arch. Pharmacol. 328:111–118 (1984).
M. Rowland and T. N. Tozer. Clinical Pharmacokinetics: Concepts and Applications Lea & Febiger, Philadelphia/London, 1989.
A. Tan, L. van den Broek, C. Van Boeckel, H. Ploegh, and J. Bolscher. Chemical modification of the glucosidase inhibitor 1-deoxynojirimycin: structure-activity relationships. J. Biol. Chem. 266:14504–14510 (1991).
C. A. M. Van Ginneken and F. G. M. Russel. Saturable pharmacokinetics in the renal excretion of drugs. Clin. Pharmacokinet. 16:38–54 (1989).
L. Peters. Renal tubular excretion of organic bases. Pharmacol. Rev. 12:1–35 (1960).
E. L. Forker. Hepatocellular uptake of inulin, sucrose and mannitol in rats. Am. J. Physiol. 219:1568–1573 (1970).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Faber, E.D., Oosting, R., Neefjes, J.J. et al. Distribution and Elimination of the Glycosidase Inhibitors 1-Deoxymannojirimycin and N-Methyl-1-Deoxynojirimycin in the Rat in Vivo . Pharm Res 9, 1442–1450 (1992). https://doi.org/10.1023/A:1015810913257
Issue Date:
DOI: https://doi.org/10.1023/A:1015810913257